PeerView Oncology & Hematology CME/CNE/CPE Video Podcast artwork

Jay B. Wish, MD - Targeting Hypoxia-Inducible Factor Stabilization as a Treatment for Anemia in Chronic Kidney Disease: Examining the Current State of the Science

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

English - May 17, 2021 23:00 - 33 minutes - ★★★★★ - 7 ratings
Science cme medical education cme credits peerview insession inreview oncology hematology cne Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: John M. Pagel, MD, PhD / Ian W. Flinn, MD, Ph - DConversations on the New Wave of Innovative Therapy in Follicular Lymphoma: Implications for Personalized Medicine
Next Episode: Hossein Borghaei, DO, MS / Sanjay Mukhopadhyay, MD / Jonathan A. Nowak, MD, PhD - The Nuances of Immunotherapy Biomarker Testing in Solid Tumors: Unraveling Complexities and Overcoming Challenges to Improve Outcomes

Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.